Clinical trial · Interventional
Combined Intrathecal Morphine and Dexmedetomidine Analgesia
Safety and Efficacy of Dexmedetomidine Addition to Intrathecal Morphine for Postoperative Analgesia in Cancer Patients Undergoing Major Abdominal Surgery
NCT02435537CI-TRIAL-00017819ITMandDEXcompletedPhase 2 / Phase 3ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The current study investigated the effect of adding dexmedetomidine to intrathecal morphine for postoperative analgesia in cancer patients undergoing major abdominal surgery.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Postoperative Pain | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacaine | Drug | — | UNRESOLVED |
| Dexmedetomidine (Precedex) | Drug | — | UNRESOLVED |
| Morphine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- ACTIVE_COMPARATOR
- label
- Intrathecal Bupivacaine
- description
- intrathecal injection of 10 mg hyperbaric bupivacaine 0.5% in 2 ml volume and 1ml of saline 0.9%
- interventionNames
- Drug: Bupivacaine
- type
- ACTIVE_COMPARATOR
- label
- Intrathecal Morphine
- description
- intrathecal injection of 10mg bupivacaine 0.5% in 2ml volume intrathecal injection of 0.5 mg morphine in 1ml volume
- interventionNames
- Drug: Bupivacaine
- Drug: Morphine
- type
- ACTIVE_COMPARATOR
- label
- Intrathecal Morphine-Dex
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 30 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: \- major abdominal cancer surgery (e.g. hemi-colectomy or cystectomy) Exclusion Criteria: * known allergy to study drugs * Significant cardiac, respiratory, renal or hepatic disease. * 2nd or 3rd degree heart block. * Coagulation disorders. * Low back pain or other back problems. * Drug or alcohol abuse. * BMI\>30kg\\m2. * Psychiatric illnesses that would interfere with perception and assessment of pain.
References
Publications (1)
- DERIVEDAbdel-Ghaffar HS, Mohamed SA, Fares KM. Combined Intrathecal Morphine and Dexmedetomidine for Postoperative Analgesia in Patients Undergoing Major Abdominal Cancer Surgery. Pain Med. 2016 Nov;17(11):2109-2118. doi: 10.1093/pm/pnw031. Epub 2016 Mar 21. PMID 27002003